India Stocks Fall as U.S. Price-Fixing Probe Rattles Drugmakers

  • Sun Pharma worst performer on Sensex; falls to one-month low
  • Software gauge rallies to 6-week high; Tata Consultancy rises

Indian stocks declined for a second day as drugmakers tumbled on speculation a U.S. justice department inquiry into price fixing could be expanded further, potentially hurting revenues in an important export market.

Sun Pharmaceutical Industries Ltd. was the worst performer on the S&P BSE Sensex, sliding 4.2 percent, to its lowest level in five weeks. Cipla Ltd. and Dr. Reddy’s Laboratories also dropped. Software makers gained on speculation export revenues will grow after the Federal Reserve raised interest rates, boosting the dollar.

IndexChange (%)Size and Scope
BSE Sensex-0.3Second session of declines
BSE Healthcare-1.4Three-week low
BSE IT+0.6Six-week high

“Drugmakers fell as the U.S. expanded the scope of the probe on drug price fixing,” said Purvi Shah, an analyst with Sharekhan Ltd. in Mumbai. “Also, Trump policy changes will lead to continued pricing pressure in the U.S. Slowing product approvals and stringent actions by the Food & Drug Administration in the recent past is also weighing on sentiment.”

Summary

Before it's here, it's on the Bloomberg Terminal.
LEARN MORE